Financing co-led by new investors Canaan and Alpha Wave, and with participation by the Global BioAccess Fund and existing investor Novo Holdings

由新投资者Canaan和Alpha Wave共同领导的融资，以及全球生物访问基金和现有投资者Novo Holdings的参与

COPENHAGEN, Denmark, Sept. 26, 2023 /PRNewswire/ -- Acesion Pharma ('Acesion' or 'the Company'), a biotech company pioneering first-in-class novel therapies for atrial fibrillation ('AF'), the most common cardiac arrhythmia, today announces that it has successfully closed an oversubscribed €45M Series B financing round.

丹麦哥本哈根，2023年9月26日/PRNewswire/-Acesion Pharma（'Acesion'或'the Company'），一家生物技术公司，开创了一流的新型心房颤动治疗（'AF'），最常见的心律失常，今天宣布它已成功关闭一项超额发行的4500万欧元B系列融资回合。

The equity financing was co-led by new US-based investors Canaan and Alpha Wave and with participation by the Global BioAccess Fund, as well as existing investor Novo Holdings..

股权融资由新的美国投资者Canaan和Alpha Wave共同领导，并由全球生物获得基金以及现有的投资者Novo Holdings参与。。

The financing will be used to advance the clinical development of AP31969, an SK ion channel inhibitor optimised for chronic oral treatment of AF. Earlier this year, Acesion demonstrated clinical proof-of-concept with AP30663, its first-in-class SK ion channel inhibitor for conversion of AF to normal sinus rhythm..

该融资将用于推进AP31969的临床开发，AP31969是一种SK离子通道抑制剂，专为AF的慢性口服治疗而优化。今年早些时候，Acesion展示了AP30663的临床概念验证，AP30663是一流的SK离子通道抑制剂。用于将AF转换为正常窦性心律。。

AP31969 will be developed for chronic oral maintenance treatment to prevent AF recurrence. Following the successful Series B financing, Acesion is well capitalised to progress AP31969 into a phase 1 and completion of a phase 2 trial.

AP31969将用于慢性口服维持治疗，以防止房颤复发。在成功进行B系列融资之后，Acision充分利用能力将AP31969推进第一阶段并完成第二阶段试验。

AF is the most common type of cardiac arrhythmia and is forecast to affect 25 million people in the US and EU by 2030. Existing drug therapies for AF are associated with the risk of serious cardiac or other adverse effects, resulting in a great need for safer drugs. Yet, there has been a lack of innovation and development with no new chronic AF drug approved for nearly 20 years.

房颤是最常见的心律失常类型，预计到2030年美国和欧盟将影响2500万人。现有的房颤药物治疗与严重心脏或其他不良反应的风险相关，因此非常需要更安全的药物。然而，近20年来没有批准新的慢性房颤药物，缺乏创新和发展。

With AP31969, Acesion is aiming to develop a safer alternative..

使用AP31969，Acision旨在开发更安全的替代方案。。

In connection with the closing of the financing, the composition of the Acesion board of directors will change to include Tim Shannon, General Partner at Canaan, and Nik Economopoulos, Analyst from Alpha Wave. Jørgen Søberg Petersen, Partner at Novo Holdings, will remain Chairman.

在融资结束时，Acision董事会的组成将改为包括Canaan的一般合作伙伴Tim Shannon和Alpha Wave的分析师Nik Economopoulos。Novo Holdings的合作伙伴JørgensøbergPetersen将继续担任主席。

Anders Gaarsdal Holst, MD, PhD, Chief Executive Officer of Acesion, said, 'The high levels of investor interest and demand that we saw during this financing speak to the strong data we have generated, both on the novel mechanism of SK channel inhibition in general and the AP31969 compound specifically.

Acesion首席执行官Anders Gaarsdal Holst博士表示，“我们在融资期间看到的高水平投资者兴趣和需求与我们所产生的强大数据有关，无论是关于SK渠道的新机制一般抑制和AP31969化合物。

This is a powerful endorsement for our team and the quality of our science. With the financing in hand, we are focused on progressing AP31969 into a phase 1 clinical trial later this year.' .

这是对我们团队和科学质量的有力认可。有了资金，我们专注于将AP31969推进今年晚些时候的1期临床试验。

Tim Shannon, MD, General Partner in Canaan, said, 'Acesion is redefining treatment for patients suffering from atrial fibrillation. The impressive preclinical data from AP31969 shows great promise and we are delighted to support Acesion in taking AP31969 through to Phase 2 completion.'

加拿大人的一般合作伙伴Tim Shannon表示，“Acesion正在重新定义患有心房颤动的患者的治疗方法。来自AP31969的令人印象深刻的临床前数据显示出巨大的希望，我们很高兴支持Acesion将AP31969提升至第2阶段完成

Jørgen Søberg Petersen, MD, PhD, MBA, Partner in Novo Holdings, said, ' As the founding and largest shareholder, Novo Holdings remains committed in helping Acesion realise the full potential of AP31969. The preclinical data is encouraging and with this series B financing in place Acesion will be able to progress the development to the important milestone of completing a phase 2 trial and thereby being ready for phase 3 programme.'.

Novo Holdings的合作伙伴JørgensøbergPetersen博士，博士，MBA表示，“作为创始和第一大股东，Novo Holdings仍然致力于帮助Acesion实现AP31969的全部潜力。临床前数据令人鼓舞，通过这一系列B融资，Acesion将能够将开发进展到完成第2阶段试验的重要里程碑，从而为第3阶段计划做好准备。

About Acesion Pharma

关于Acesion Pharma

Acesion builds on 20 years of know-how with development of small-molecule SK inhibitors and is the world leader in the field of SK channel inhibition, being the only company able to identify and progress SK channel inhibitors into clinical trials. In pre-clinical studies, inhibiting the SK channels has been shown to result in pronounced antiarrhythmic effects in the atria while avoiding effects on the ventricles, the major chambers of the heart and the source of most safety issues with existing drugs.

随着小分子SK抑制剂的发展，Acesion建立在20年的专业知识基础上，并且是SK通道抑制领域的世界领先者，是唯一能够识别和推进SK通道抑制剂进入临床试验的公司。在临床前研究中，已证明抑制SK通道可在心房中产生明显的抗心律不齐作用，同时避免对心室，心脏的主要腔室以及现有药物最安全问题的根源产生影响。

Furthermore, the SK channel has strong genetic validation, with genes encoding the SK channels having one of the strongest associations to AF in human genome-wide association studies. Acesion's AP30663 IV is a short acting conversion therapy for hospitals that has completed a phase 2 trial proving the value of this first-in-class mechanism in AF and thereby de-risking Acesion's broader SK inhibitor pipeline.

此外，SK通道具有强大的遗传验证，在人类全基因组关联研究中，编码SK通道的基因与AF的关联最强。Acesion的AP30663 IV是一种针对医院的短效转换疗法，已经完成了一项2期试验，证明了这种一流机制在房颤中的价值，从而降低了Acesion更广泛的SK抑制剂管道的风险。

Acesion's oral program is designed and engineered using in house knowhow to optimise for, and meet, very high hurdles in both efficacy and particularly safety where existing treatments fall short of patient needs. Acesion Pharma is backed by Novo Holdings A/S, Canaan, Alpha Wave Alpha Wave Ventures, Global BioAccess Fund, Wellcome Trust, Broadview Ventures and FC Capital..

Acesion的口腔计划是使用内部技术设计和设计的，用于优化和满足非常高的功效障碍，特别是现有治疗无法满足患者需求的安全性障碍。Acesion Pharma得到Novo Holdings A/S，Canaan，Alpha Wave Alpha Wave Ventures，Global BioAccess Fund，Wellcome Trust，Broadview Ventures和FC Capital的支持。。

https://www.acesionpharma.com/

https://www.acesionpharma.com/

About Canaan

关于卡纳

Canaan is an early-stage venture capital firm that invests in entrepreneurs with visionary ideas. With $6.8 billion under management, a diversified fund, and hundreds of exits to date, Canaan partners with entrepreneurs building the next generation of technology and healthcare companies that will transform how we live, work, and thrive.

加拿大人是一家早期的风险投资公司，投资于有远见的企业家。迄今为止，管理层拥有68亿美元，多元化基金和数百次退出，加拿大与企业家合作，建立下一代技术和医疗保健公司，这将改变我们的生活，工作和发展方式。

To learn more about our people and our portfolio, please visit: www.canaan.com.

要了解有关我们的人员和我们的产品组合的更多信息，请访问：www.canaan.com。

About Alpha Wave

关于阿尔法波

Alpha Wave is a global investment company that manages a variety of partnerships that separately focus on three main verticals: private equity (venture and growth), credit, and public markets. It is led by Rick Gerson, Navroz Udwadia, and Ryan Khoury. Alpha Wave has offices in New York, Miami, London, Monaco, Madrid, Abu Dhabi, Tel Aviv, Bangalore, Jakarta, and Sydney.

Alpha Wave是一家全球投资公司，负责管理各种合作伙伴关系，分别关注三个主要领域：私募股权（风险和增长），信贷和公共市场。它由Rick Gerson，Navroz Udwadia和Ryan Khoury领导。Alpha Wave在纽约，迈阿密，伦敦，摩纳哥，马德里，阿布扎比，特拉维夫，班加罗尔，雅加达和悉尼设有办事处。

Its flagship global venture and growth fund, Alpha Wave Ventures, aims to invest in best-in-class venture and growth-stage companies and endeavors to be helpful long-term partners to the founders and management teams. For more information, please visit www.alphawaveglobal.com..

其旗舰全球风险和增长基金Alpha Wave Ventures旨在投资一流的风险和增长阶段公司，并努力成为创始人和管理团队的长期合作伙伴。欲了解更多信息，请访问www.alphawaveglobal.com。。

About the Global BioAccess Fund

关于全球生物安全基金

The Global BioAccess Fund invests in companies developing novel therapeutics and devices to address serious unmet medical needs in oncology, cardiovascular, neurological, and rare diseases. Leveraging the deep life sciences expertise and global reach of its management, scientific advisors, and partners, the Global BioAccess Fund actively supports ventures who are in clinical-stage development, including IND enabling studies and clinical trials.

全球生物安全基金投资于开发新型疗法和设备的公司，以解决肿瘤学，心血管疾病，神经疾病和罕见疾病中严重未满足的医疗需求。全球生物安全基金利用其深层生命科学专业知识和管理层，科学顾问和合作伙伴的全球影响力，积极支持处于临床阶段开发阶段的企业，包括IND启用研究和临床试验。

See www.globalbioaccess.com..

请访问www.globalbioaccess.com。。

About Novo Holdings

关于Novo Holdings

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation..

Novo Holdings是一家控股和投资公司，负责管理Novo Nordisk基金会的资产和财富。Novo Holdings的目的是通过为Novo Nordisk基金会的资产产生有吸引力的长期回报来改善人们的健康以及社会和地球的可持续性。。

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor.

Novo Holdings由Novo Nordisk Foundation完全拥有，是Novo Nordisk A/S和Novozymes A/S的控股股东，并以长期回报视角管理投资组合。除了管理广泛的股票，债券，房地产，基础设施和私募股权资产组合外，Novo Holdings是世界领先的生命科学投资者。

Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2022, Novo Holdings had total assets of EUR 108 billion..

通过其种子，风险，成长和主要投资团队，Novo Holdings在所有开发阶段都投资于生命科学公司。截至2022年底，Novo Holdings的总资产为1080亿欧元。。

www.novoholdings.dk

www.novoholdings.dk

About atrial fibrillation (AF)

关于心房颤动（AF）

AF is the most common type of cardiac arrhythmia mainly affecting the elderly population. Lifetime risk for development of AF is estimated at more than one in three. It is forecast to affect 25 million people in the US and EU by 2030. AF is characterized by chaotic electrical activity in the upper chambers of the heart, the atria, resulting in an irregular and high heart rate.

房颤是主要影响老年人群的最常见的心律失常类型。发生房颤的终生风险估计超过三分之一。预计到2030年将影响美国和欧盟2500万人。AF的特征在于心脏上腔，心房中的混乱电活动，导致心率不规则和高。

AF is associated with impaired quality of life, increased rate of hospitalization, and a five-fold increased risk of stroke. Increasing evidence suggests that patients with AF also face a higher risk of cognitive dysfunction and dementia..

房颤与生活质量受损，住院率增加以及中风风险增加5倍有关。越来越多的证据表明，房颤患者也面临更高的认知功能障碍和痴呆风险。。

AF is often treated by electrical shock to bring the heart back to its normal rhythm (conversion). This requires general anesthesia in a hospital setting. In addition, many patients are likely to benefit from chronic treatment to prevent AF and maintain normal sinus rhythm. Existing drug therapies for cardioversion or prevention of AF are associated with risk of serious cardiac or other adverse effects, resulting in a great need for safer drugs.

AF通常通过电击治疗，使心脏恢复正常节律（转换）。这需要在医院环境中进行全身麻醉。此外，许多患者可能从长期治疗中受益，以预防房颤并维持正常的窦性心律。现有的用于复律或预防房颤的药物疗法与严重心脏或其他不良反应的风险相关，导致对更安全药物的极大需求。

Yet, there has been a lack of innovation and development with no new chronic AF drug approved for nearly 20 years. A landmark New England Journal of Medicine published clinical trial (https://doi.org/10.1056/NEJMoa2019422) has shown that sinus rhythm maintenance treatment improves survival and long-term outcomes for AF patients..

然而，近20年来没有批准新的慢性房颤药物，缺乏创新和发展。具有里程碑意义的新英格兰医学杂志发表临床试验(https://doi.org/10.1056/NEJMoa2019422)研究表明，窦性心律维持治疗可改善AF患者的生存率和长期预后。。

SOURCE Acesion Pharma

来源Acesion Pharma